A new study published in Cell has unveiled a first-of-a-kind optogenetic screening platform, developed by scientists at Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases. The new publication demonstrates the platform’s capabilities by applying it to the integrated stress response (ISR), a key aging- and disease-associated signaling pathway implicated in neurodegeneration, cancer and viral infection.
Optogenetic screening platform for drug discovery introduced
